Last reviewed · How we verify
NCT04609683
Measuring Hydration Levels of Healthy and Heart Failure Patients Before, During, and After an Electrophysiology (EP) Procedure
NA trial testing AleriTM sensors in Cardiac Arrhythmia in 19 participants. Completed in 5 November 2023.
21 November 2022
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 19 |
| Start date | 19 September 2022 |
| Primary completion | 21 November 2022 |
| Estimated completion | 5 November 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- AleriTM sensors
Conditions studied
- Cardiac Arrhythmia — all drugs for Cardiac Arrhythmia →
Sponsor
NYU Langone Health — full company profile →
Who can join
Adults 18 to 100, any sex, with Cardiac Arrhythmia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Subjects will be consented to wear the AleriTM sensor prior to, during, and after an Electrophysiology Procedure. During this time, the system will measure the following parameters from subjects: HR, temperature, saline volume/rate, urine production volume, USG, BPO. Data will be retrospectively analyzed to determine if the system effectively operates under these conditions, and can effectively monitor hydration levels of subjects compared to currently available methods.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04609683
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiac Arrhythmia
Currently open trials in the same condition.
- NCT06870175 — Smart Textile ECG Monitoring · NA · recruiting
- NCT07205367 — Validation Study: Extended Wear Performance of the Zio Monitor - SHASTA II · NA · active not recruiting
- NCT06490432 — Pattern of Cardiac Arrhythmia in Patients With MASLD · recruiting
- NCT06096246 — Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF) · NA · recruiting
- NCT06696170 — CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation · NA · recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04609683 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 29 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04609683.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing